Toxicodynamic Evaluation of a Cisplatin–Chondroitin Sulfate Complex Using a Perfused Kidney and Human Proximal Tubular Cells

REFERENCES

• Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC. A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol. 1988;6:1031–1040.
   PubMed Web of Science ®Google Scholar
• Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: A review. Am J Med Sci. 2007;334:115–124.
   PubMed Web of Science ®Google Scholar
• Shord SS, Thompson DM, Krempl GA, Hanigan MH. Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. Anticancer Drugs. 2006;17:207–215.
   PubMed Web of Science ®Google Scholar
• Choie DD, del Campo AA, Guarino AM. Subcellular localization of cis-dichlorodiammineplatinum(II) in rat kidney and liver. Toxicol Appl Pharmacol. 1980;55:245–252.
   PubMed Web of Science ®Google Scholar
• Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther. 2009;86:396–402.
   PubMed Web of Science ®Google Scholar
• Santoso JT, Lucci JA, 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: A randomized trial. Cancer Chemother Pharmacol. 2003;52:13–18.
   PubMed Web of Science ®Google Scholar
• Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the nephrotoxicity of cisplatin and other platinum compounds: A review of some recent research. Food Chem Toxicol. 2006;44:1173–1183.
   PubMed Web of Science ®Google Scholar
• Hausheer FH, Kanter P, Cao S, . Modulation of platinum-induced toxicities and therapeutic index: Mechanistic insights and first- and second-generation protecting agents. Semin Oncol. 1998;25:584–599.
   PubMed Web of Science ®Google Scholar
• Zhang JS, Shen-Feng MA, Suenaga A, Otagiri M. Stability of a cisplatin-chondroitin sulfate A complex in plasma and kidney in terms of protein binding. Biol Pharm Bull. 2001;24:970–972.
   PubMedGoogle Scholar
• Zhang JS, Anraku M, Kadowaki D, Spectroscopic studies of interactions of chondroitin sulfates with cisplatin. Carbohydr Res. 2011;346:631–637.
   Google Scholar
• Zhang JS, Imai T, Suenaga A, Otagiri M. Molecular-weight-dependent pharmacokinetics and cytotoxic properties of cisplatin complexes prepared with chondroitin sulfate A and C. Int J Pharm. 2002;240:23–31.
   PubMed Web of Science ®Google Scholar
• Zhang JS, Imai T, Otagiri M. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin. Arch Toxicol. 2000;74:300–307.
   PubMed Web of Science ®Google Scholar
• Newton Jr. JF, Hook JB. Isolated perfused rat kidney. Methods Enzymol. 1981;77:94–105.
   PubMedGoogle Scholar
• Imai T, Fujii K, Shiraishi S, Otagiri M. Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates. J Pharm Sci. 1997;86:244–247.
   PubMedGoogle Scholar
• Blachley JD, Hill JB. Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med. 1981;95:628–632.
   PubMed Web of Science ®Google Scholar
• Rasoulian B, Jafari M, Mahbod M, . Pretreatment with oxygen protects rat kidney from cisplatin nephrotoxicity. Ren Fail. 2010;32:234–242.
   PubMed Web of Science ®Google Scholar
• Chirino YI, Pedraza-Chaverri J. Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity. Exp Toxicol Pathol. 2009;61:223–242.
   PubMed Web of Science ®Google Scholar
• Ivanov AI, Christodoulou J, Parkinson JA, . Cisplatin binding sites on human albumin. J Biol Chem. 1998;273:14721–14730.
   PubMed Web of Science ®Google Scholar
• Neault JF, Tajmir-Riahi HA. Interaction of cisplatin with human serum albumin. Drug binding mode and protein secondary structure. Biochim Biophys Acta. 1998;1384:153–159.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui K. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol. 2010;80:1762–1767.
   PubMed Web of Science ®Google Scholar
• Aleksunes LM, Augustine LM, Scheffer GL, Cherrington NJ, Manautou JE. Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology. 2008;250:82–88.
   PubMed Web of Science ®Google Scholar
• Burger H, Zoumaro-Djayoon A, Boersma AW, . Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol. 2010;159:898–908.
   PubMed Web of Science ®Google Scholar
• Gately DP, Howell SB. Cellular accumulation of the anticancer agent cisplatin: A review. Br J Cancer. 1993;67:1171–1176.
   PubMed Web of Science ®Google Scholar
• Cornelison TL, Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993;50:147–158.
   PubMed Web of Science ®Google Scholar
• Vickers AE, Rose K, Fisher R, Saulnier M, Sahota P, Bentley P. Kidney slices of human and rat to characterize cisplatin-induced injury on cellular pathways and morphology. Toxicol Pathol. 2004;32:577–590.
   PubMed Web of Science ®Google Scholar
• Lajer H, Kristensen M, Hansen HH, . Magnesium depletion enhances cisplatin-induced nephrotoxicity. Cancer Chemother Pharmacol. 2005;56:535–542.
   PubMed Web of Science ®Google Scholar